 |
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 20, 2013
|
8.9 KB |
|
| |
SAN RAFAEL, Calif., May 20, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on May 15, 2013, the compensation committee of BioMarin's board of directors approved the grant to 32 employees of stock options to purchase 33,900 shares of common stock in the aggregate and the grant to 29 of the 32 employees of 7,...
|
|
BioMarin Announces BMN-673 Data in Breast and Ovarian Cancers to be Released at ASCO
May 16, 2013
|
9.7 KB |
|
| |
SAN RAFAEL, Calif., May 16, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that data from its ongoing Phase 1/2 trial for BMN-673 for genetically-defined cancers will be released at the American Society of Clinical Oncology (ASCO) meeting in Chicago on June 3, 2013. At ASCO, the company will present data from 18...
|
|
BioMarin to Present at the UBS Global Healthcare Conference
May 14, 2013
|
7.6 KB |
|
| |
SAN RAFAEL, Calif., May 14, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Chief Financial Officer at BioMarin, will present a company update at the UBS Global Healthcare Conference on Tuesday, May 21, 2013 at 9:00 a.m. ET. Interested parties may access a live audio webcast of the conference...
|
|
BioMarin to Present at the Baird Growth Stock Conference
May 2, 2013
|
7.6 KB |
|
| |
SAN RAFAEL, Calif., May 2, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Maher, Senior Vice President of Product Development at BioMarin, will present a company update at the Baird Growth Stock Conference on Tuesday, May 7, 2013 at 9:45 a.m. CT. Interested parties may access a live audio webcast of the...
|
|
BioMarin Announces First Quarter 2013 Financial Results
Apr 25, 2013
|
30.8 KB |
|
| |
Total Revenue Continues Steady Growth of 10 Percent; Progress on All Aspects of the Business
Conference Call and Webcast to Be Held Today at 5:00 p.m. ETFinancial Highlights ($ in millions, except per share data, unaudited)
Q1 2013Q1 2012Percent Change
Total BioMarin Revenue
$ 127.9
$ 116.6
9.7%
Tota...
|
|
BioMarin Submits Vimizim MAA to EMA for the Treatment of MPS IVA
Apr 24, 2013
|
10.2 KB |
|
| |
SAN RAFAEL, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Vimizim (BMN-110, elosulfase alfa), an enzyme replacement therapy under evaluation for the treatment of patients with the rare lyso...
|
|
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 18, 2013
|
8.9 KB |
|
| |
SAN RAFAEL, Calif., April 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on April 15, 2013, the compensation committee of BioMarin's board of directors approved the grant to 27 employees of stock options to purchase 32,500 shares of common stock in the aggregate and the grant to 25 of the 27 employees o...
|
|
BioMarin to Host First Quarter 2013 Financial Results Conference Call and Webcast on Thursday, April 25 at 5:00 p.m. ET
Apr 4, 2013
|
9.5 KB |
|
| |
SAN RAFAEL, Calif., April 4, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 25, at 5:00 p.m. ET to discuss first quarter 2013 financial results.
U.S. / Canada Dial-in Number: 877.3...
|
|
BioMarin Submits CTA for BMN-190 for Batten Disease
Apr 1, 2013
|
10.8 KB |
|
| |
SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has submitted a Clinical Trial Application (CTA) with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for BMN-190, a recombinant human tripeptidyl peptidase 1 (rhTPP1) for the treatment of patients with...
|
|
BioMarin Submits Vimizim BLA to the U.S. FDA for the Treatment of MPS IVA
Apr 1, 2013
|
11.2 KB |
|
| |
SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Vimizim (BMN-110, elosulfase alfa), an enzyme replacement therapy under evaluation for the treatment of patients with the rare lys...
|
|
BioMarin Completes Additional Partial Exchange of Convertible Notes Due 2017 for Common Stock
Mar 25, 2013
|
10.2 KB |
|
| |
SAN RAFAEL, Calif., March 25, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that an additional six holders of its 1.875% Convertible Senior Subordinated Notes due 2017 have agreed to exchange $75.8 million in aggregate principle amount of the notes for approximately 3.7 million shares of the Company's common st...
|
|
BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Development
Mar 19, 2013
|
20.4 KB |
|
| |
BMN-701 Meaningfully Improves Respiratory Endpoints
Phase 2/3 Switch Study Expected to Begin by December 2013
Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
SAN RAFAEL, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today results from POM-001, the Phase 1/2 trial for BMN-701...
|
|
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 19, 2013
|
10.6 KB |
|
| |
NOVATO, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on March 15, 2013, the compensation committee of BioMarin's board of directors approved the grant to 20 employees of stock options to purchase 32,100 shares of common stock in the aggregate and the grant to 15 of the 20 employees of 4,...
|
|
BioMarin Completes Partial Exchange of Convertible Notes Due 2017 for Common Stock
Mar 18, 2013
|
10.4 KB |
|
| |
SAN RAFAEL, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that seven holders of its 1.875% Convertible Senior Subordinated Notes due 2017 have agreed to exchange approximately $139.2 million in aggregate principal amount of the notes for approximately 6.8 million shares of the Company's common...
|
|
BioMarin to Attend Upcoming Conferences: Cowen Healthcare Conference, Credit Suisse Global Healthcare Conference and Barclays Global Healthcare Conference
Feb 28, 2013
|
9.8 KB |
|
| |
SAN RAFAEL, Calif., Feb. 28, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that BioMarin will attend the Cowen Healthcare Conference in Boston on March 4th, the Credit Suisse Global Healthcare Conference in London on March 6th and the Barclays Global Healthcare Conference in Miami on March 12th.
Dan Maher, ...
|
|
BioMarin Announces Fourth Quarter and Full Year 2012 Financial Results
Feb 21, 2013
|
35.4 KB |
|
| |
Total Revenue in 2012 Exceeds $500 Million
PEG-PAL End of Phase 2 Meeting Completed, Phase 3 to Begin Next Quarter
Conference Call and Webcast to Be Held Today at 5:00 p.m. ETFinancial Highlights ($ in millions, except per share data, unaudited)
FY 2012FY 2011Percent Change
Total BioMarin Revenue
$ 500.7
$ 441...
|
|
BioMarin Licenses Factor VIII Gene Therapy Program for Hemophilia A From University College London and St. Jude Children's Research Hospital
Feb 21, 2013
|
14.5 KB |
|
| |
SAN RAFAEL, Calif., Feb. 21, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has licensed a Factor VIII gene therapy program for hemophilia A from University College London (UCL) and St. Jude Children's Research Hospital. The company expects to select a development candidate this year, initiate and comple...
|
|
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 20, 2013
|
10.7 KB |
|
| |
SAN RAFAEL, Calif., Feb. 20, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on February 15, 2013, the compensation committee of BioMarin's board of directors approved the grant to 31 employees of stock options to purchase 65,200 shares of common stock in the aggregate and the grant to 26 of the 31 employees...
|
|
BioMarin to Attend Upcoming Conferences: Canaccord Genuity Orphan Drug Day, Citibank Global Healthcare Conference and RBC Capital Markets Healthcare Conference
Feb 19, 2013
|
9.4 KB |
|
| |
SAN RAFAEL, Calif., Feb. 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that BioMarin will attend the Canaccord Genuity Orphan Drug Day on February 25th, the Citibank Global Healthcare Conference on February 26th and the RBC Capital Markets Healthcare Conference on February 26th.
Dan Spiegelman, Chief Fi...
|
|
BioMarin Announces Kuvan Significantly Improves Inattentiveness in Kuvan Responding PKU Patients
Feb 19, 2013
|
14.6 KB |
|
| |
SAN RAFAEL, Calif., Feb. 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today results from the PKU-016 ASCEND study, the largest randomized controlled trial evaluating neuropsychiatric outcomes in phenylketonuria (PKU) patients treated with the approved drug Kuvan (sapropterin dihydrochloride).
The study evalu...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
